Publications by authors named "J B Kurtz"
Energy drinks are a commonly consumed beverage, and studies suggest a possible performance-enhancing effect. A Google Scholar search using the keywords "energy drinks" and "exercise" yields numerous results, underscoring the voluminous research on this topic. However, there are questions regarding the effectiveness and safety of energy drinks.
View Article and Find Full Text PDFObjective: Therapeutic interventions for epithelial ovarian cancer (EOC) have increased greatly over the last decade but improvements outside of biomarker selected therapies have been limited. There remains a pressing need for more effective treatment options that can prolong survival and enhance the quality of life of patients with EOC. In contrast to the significant benefits of immunotherapy with immune checkpoint inhibitors (CPI) seen in many solid tumors, initial experience in EOC suggests limited efficacy of CPIs monotherapy.
View Article and Find Full Text PDFArticle Synopsis
- The study focused on individualized dosing of niraparib for patients with platinum-sensitive recurrent ovarian cancer (PSROC), revealing that most patients required treatment modifications due to adverse events (AEs) during the first three months.
- A significant proportion of patients (62%) experienced AEs, with common issues including fatigue, insomnia, and thrombocytopenia, highlighting the physical and emotional burden of the therapy.
- The findings indicated that physicians often underestimated these symptoms, emphasizing the importance of patient self-reporting for a comprehensive understanding of treatment-related challenges.
Objective: To evaluate the prognostic impact of circulating tumor DNA (ctDNA) detection at diagnosis (T0) and its early decrease after one cycle (T1) of neoadjuvant chemotherapy (NACT) in patients with advanced epithelial ovarian cancer (EOC) included in the CHIVA trial (NCT01583322).
Methods: Blood samples were collected at T0 and before each administration of NACT. Circulating tumor DNA detection was performed by next-generation sequencing.
Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial.
Gynecol Oncol
December 2024
Purpose: The CDK4/6 inhibitor palbociclib inhibits cyclin A, which is overexpressed in endometrial cancer. Combining palbociclib with endocrine therapy improves efficacy in hormone receptor-positive breast cancer. We investigated palbociclib combined with endocrine therapy for estrogen receptor-positive advanced/recurrent endometrial cancer.
View Article and Find Full Text PDF